First Eagle Investment Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3
| Closed | -$101 | – | 402 |
|
|
2023
Q1 | $101 | Sell |
3
-59,457
| -100% | -$2.08M | ﹤0.01% | 395 |
|
|
2022
Q4 | $2.09M | Buy |
59,460
+9,901
| +20% | +$330K | 0.01% | 259 |
|
|
2022
Q3 | $1.46M | Sell |
49,559
-17,451
| -26% | -$661K | ﹤0.01% | 272 |
|
|
2022
Q2 | $3.65M | Buy |
67,010
+19,483
| +41% | +$1.08M | 0.01% | 105 |
|
|
2022
Q1 | $2.59M | Buy |
47,527
+14,252
| +43% | +$774K | 0.01% | 121 |
|
|
2021
Q4 | $1.83M | Buy |
33,275
+18,363
| +123% | +$955K | ﹤0.01% | 92 |
|
|
2021
Q3 | $712K | Buy |
14,912
+5,871
| +65% | +$295K | ﹤0.01% | 93 |
|
|
2021
Q2 | $450K | Buy |
9,041
+8,524
| +1,649% | +$410K | ﹤0.01% | 93 |
|
|
2021
Q1 | $23K | Buy |
517
+258
| +100% | +$11.7K | ﹤0.01% | 95 |
|
|
2020
Q4 | $12K | Buy |
+259
| New | +$11.9K | ﹤0.01% | 93 |
|
|
2018
Q1 | – | Sell |
-1
| Closed | – | – | 227 |
|
|
2017
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 343 |
|
|
2017
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 353 |
|
|
2017
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 336 |
|
|
2017
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 327 |
|
|
2016
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 343 |
|
|
2016
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 355 |
|
|
2016
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 361 |
|
|
2016
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 343 |
|
|
2015
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 337 |
|
|
2015
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 326 |
|
|
2015
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 319 |
|
|
2015
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 342 |
|
|
2014
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 346 |
|
|
2014
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 343 |
|
|
2014
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 353 |
|
|
2014
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 396 |
|
|
2013
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 379 |
|
|
2013
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 366 |
|
|
2013
Q2 | $0 | Buy |
+1
| New | +$63 | ﹤0.01% | 355 |
|
Other funds holding GSK
JEST
